In an effort to deliver cutting-edge therapies to patients with major depression with convenient access to their local communities, McLean Hospital is expanding its treatment services with the opening of a neurotherapeutics clinic at the McLean SouthEast campus at 52 Oak Street in Middleborough, Massachusetts.
The new clinic offers transcranial magnetic stimulation (TMS) and esketamine (Spravato®) for patients with major depressive disorder and treatment-resistant depression. Since these treatments require frequent appointments for patients, this new location aims to provide a more convenient access point for care for residents in southern Massachusetts, Cape Cod, and Rhode Island.
The new clinic represents an ongoing effort for McLean Hospital, a member of Mass General Brigham, to expand its treatment offerings into the region through its McLean SouthEast campus and its growing list of services.
“There is a significant demand for treatments for major depression, and we are delighted to be able to offer them to patients closer to their homes,” said Paula Bolton, MS, CNP, ANP-BC, program director of the Psychiatric Neurotherapeutics Program and interim associate chief nursing officer at McLean.
“As these treatments require frequent administration, we sought to meet the needs of patients who in the past might have had to travel further to McLean’s main Belmont campus for these therapies.”
Safe and Effective Newer Therapies for Patients With Depression
The treatment offerings in the new neurotherapeutics clinic at McLean SouthEast at Oak Street are approved by the U.S. Food and Drug Administration for treating patients with major depression.
TMS uses focused magnetic impulses to non-invasively stimulate the brain in the prefrontal cortex, the region of the brain associated with mood regulation. Patients typically receive 20 to 30 treatments over four to six weeks (five times per week, which may also be followed by a taper phase). The course of treatment varies according to each individual.